Last edition
News about "investigational therapies"
US FDA Grants Fast Track Designation to OncoC4's Cesalatamig
US FDA grants Fast Track Designation to OncoC4’s cesalatamig for patients with NSCLC whose disease has progressed following PD-(L)1-targeted immunotherapy and platinum-based chemotherapy.
Investigational Therapies | 17/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members